4 March 2026 - Top Stories

AI is moving from concept to clinic in Australia, with several health‑tech advances approaching routine use. The developments span personalised screening, at‑point diagnostics and digital patient journeys.

Emerging AI tools for breast screening are advancing. The BRAIx risk score uses mammogram images to estimate a woman's risk of developing breast cancer over four years. The study in Lancet Digital Health drew on nearly 400,000 Australian scans for training and about 96,000 Australian cases for testing, with validation in a Swedish cohort of more than 4,500 women. It outperformed conventional risk factors such as breast density and family history, suggesting targeted screening pathways may become more feasible.

Despite potential, Australian health AI adoption is not scaling. A late 2025 Appian survey of 500 health workers found 60 per cent are piloting AI or running small tests, but only 12 per cent have deployed AI across multiple care or admin functions. The forecast remains optimistic about a $13 billion annual uplift by 2030, yet data quality, weak system integration and misaligned use cases block scale. Experts urge end‑to‑end workflows and solid data foundations as prerequisites.

Pathways, a digital platform under development, aims to support Australians making mental health related income protection claims. The project brings together the Digital Health CRC, the University of Sydney, TAL and Workcom, with University of Sydney researchers leading design and co‑creation. The goal is to guide claimants through options, connect them with recovery services and reduce stress during the process.

On diagnostics, researchers have developed a portable CRISPR based multi‑pathogen STI test. The Peter Doherty Institute device can detect four infections in a single visit and also flags a resistance marker in gonorrhoea. It accepts urine or swabs and moves toward implementation trials after laboratory validation, with a view to improving access in regional and remote Australia.

TGA warnings about fake GLP‑1 weight loss products highlight safety concerns in the weight‑management market. Recent tests on imports show many products marketed as GLP‑1 receptor agonists do not contain the drug. Regulators are asking clinicians to warn patients and to report adverse events, signalling tighter import controls and more oversight for online marketplaces and health apps.

Evidence from aged care shows the importance of GP continuity. A large study across thousands of facilities found residents with a regular GP had better outcomes, including fewer deaths and hospital visits, compared with those who saw unfamiliar clinicians. The findings point to interoperability and care design as levers for scale in value‑based care.

• Advance BRAIx‑based personalised screening to pilot and scale with regulatory validation.
• Invest in data quality and interoperability to unlock AI scale across care.
• Move Pathways from design to a user‑ready platform for mental health claims.
• Support field‑ready CRISPR STI diagnostics to improve regional access.
• Strengthen safety and oversight for unregistered GLP‑1 products.
• Promote GP continuity and data governance to boost aged‑care outcomes.